logo-loader

Allergy Therapeutics boss says the firm is outperforming its competitors

Published: 03:03 14 Jan 2016 AEDT

Chief executive of Allergy Therapeutics (LON:AGY), Manuel Llobet, said maintaining double digit growth in the first half for consecutive years “demonstrates our robust business model.”

“We are outperforming our competitors and we are taking market share,” he added, as the firm gave an upbeat assessment of current trading.

It expects revenues to be in the order of £31.5mln in the first half of its financial year, which equates to a 12% rise at constant currencies.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 50 minutes ago